Arcus Biosciences (RCUS) had its price target raised by Citigroup Inc. from $44.00 to $45.00. They now have a "buy" rating on the stock.
Arcus Biosciences (RCUS) had its price target raised by Leerink Partners from $36.00 to $49.00. They now have an "outperform" rating on the stock.
Arcus Biosciences (RCUS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.
Arcus Biosciences Puts Casdatifan Kidney Cancer Data At Center Stage [Yahoo! Finance]
Arcus Biosciences Q4 Earnings Call Highlights [Yahoo! Finance]